Vogler, Sabine; Zimmermann, Nina; Habimana, Katharina (2014): Study of the policy mix for the reimbursement of medicinal products. Proposal for a best practice-based approach based on stakeholder assessment. Gesundheit Österreich Forschungs- und Planungs GmbH und SOGETI, Wien.

[img]
Preview
Text
Study of the policy mix for the reimbursement of medicinal products.pdf

Download (4MB) | Preview

Abstract

EU Member States have been struggling to address the challenge of reconciling different, partially conflicting policy objectives related to the reimbursement of medicines: patient access and equity, cost-containment and sustainable funding, and granting reward for innovation to the pharmaceutical industry. Processes such as the High Level Pharmaceutical Forum (2005 to 2008) and the Platform on Access to Medicines in Europe under the Process on Corporate Responsibility in the field of Pharmaceuticals (2010 to 2013), led by the European Commission and involving Member States and stakeholders, and the ‘Reflection process - Towards modern, responsive and sustainable health systems’ of the sub-group on ‘Cost-effective use of medicines’, led by the Netherlands, should support the Member States in implementing policies to address this challenge. The general objective of this study was to explore which policy mix related to the reimbursement (funding) of medicines the consulted stakeholders consider as ideal and, based on their assessments investigated in a Multi-Criteria Decision Analysis (MCDA), to develop a proposal for the best practice-based approach for such a policy mix (reconciling the different – often conflictive – policy objectives).

Item Type: Monograph (Project Report)
Subjects: OEBIG > Pharmaoekonomie
Date Deposited: 09 Aug 2017 14:38
Last Modified: 09 Aug 2017 14:38
URI: https://jasmin.goeg.at/id/eprint/223